



March 12, 2024

Company name: Modalis Therapeutics Corporation

Stock exchange listing: Tokyo Stock Exchange

Code number: 4883

URL: <https://www.modalistx.com/en/>

Representative: Haruhiko Morita

Notice of Change in a Major Shareholder

Modalis Therapeutics Corporation (hereafter, “the Company”) hereby announces change in a major shareholder of the Company as of November 8th, 2023.

1. Background of the change

As disclosed in the "Notice of Issuance of 1st Series Unsecured Convertible Bond Type Bonds with Stock Acquisition Rights (with Conversion Price Amendment Clause) and 12th Series Stock Acquisition Rights (with Exercise Price Amendment Clause) by Third Party Allotment" dated November 7, 2023, our major shareholder and largest shareholder, Life Science Innovation Management Inc. (the "Lender"), the largest shareholder of the Company, lends a portion of its common stock to EVO FUND (the "Borrower"), the allottee of the Convertible Bond and the Stock Acquisition Rights. The Lender and the Borrower executed a share certificate loan agreement (the "Share Certificate Loan Agreement") under which the Lender lent shares of common stock of the Company held by the Lender to the Borrower. The Company hereby announces that there was a change in its major shareholder as a result of the execution of the Share Certificate Loan Agreement executed on November 8, 2023.

2. Overview of a major shareholder

(1) Name	Lifescience Innovation Management Inc.
(2) Address	1-9-6 Nihonbashi-Bakurocho Chuo Tokyo 1030002 JAPAN
(3) Title and name of representative	President / Akihiko Morita
(4) Business	Asset management

3. Number of voting rights (number of shares) held by the shareholder before and after the change and percentage of the total number of voting rights held by all shareholders

	Number of voting rights (Number of shares held)	Ratio to the number of the voting rights held by all shareholders	Ranking among shareholders
Before change (As of June 30, 2023)	48,318 units (4,831,800share)	15.32%	1 st place
After change (As of November 8, 2023)	28,318 units (2,831,800share)	8.98%	1 st place

※1 The ratio to the number of the voting rights held by all shareholders before change is calculated with 31,577,500 the number of voting rights held by all shareholders as of June 30, 2023 (calculated by subtracting 35,537 shares with no voting rights from 315,419 shares of the total number of shares issued).

※2 Ratio to the number of the voting rights held by all shareholders is rounded to the first decimal place.

※3 The ranking of major shareholders after the change is based on the shareholder register as of June 30, 2023, which is the assumed ranking of major shareholders at the Company. The Company has confirmed that the ranking of major shareholders is No. 1 in the list of shareholders as of December 31, 2023.

4. Future outlook

The share certificate loan agreement stipulates that the borrower shall exercise voting and other rights with respect to the loaned shares in accordance with the instructions of the lender. Therefore, this change will have no impact on the Company's management and business.

(The end of document)